Illumina’s first quarter results reflected ongoing challenges in the global genomics market, as the company’s performance fell short of market expectations, prompting a negative reaction from investors. Management attributed recent revenue declines to a combination of restricted instrument exports to China, a constrained research funding environment in the U.S., and evolving trade dynamics. CEO Jacob Thaysen acknowledged these headwinds, emphasizing, "Developments around China, U.S. funding uncertainty, and global trade dynamics have introduced new pressures for our customers." Despite these pressures, Illumina highlighted continued strength in clinical markets and ongoing adoption of its NovaSeq X platform.

Is now the time to buy ILMN? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions Illumina’s Q1 Earnings Call

• Doug Schenkel (Wolfe): Asked about the outlook for research and clinical revenue growth given headwinds in China. CEO Jacob Thaysen reiterated that clinical strength is offsetting research declines, and cost actions are designed to mitigate China’s impact.
• Dave Westenberg (Piper Sandler): Questioned the drivers behind mid- and low-throughput consumables weakness. Thaysen pointed to a mix of funding constraints, customer migration to service providers, and moderate competitive pressures, particularly in China.
• Jack Meehan (Nephron): Inquired whether tariff dynamics influenced purchasing behavior. Thaysen responded that demand remained stable, with only minor pull-ins observed in China.
• Tycho Peterson (Jefferies): Pressed on Illumina’s ability to implement pricing increases given aggressive competitor offerings. Thaysen and Dhingra expressed confidence that customers value reliability and support, even as some competitors discount or give away sequencing products.
• Mike Ryskin (Bank of America): Sought clarity on the sustainability of China and research revenue into 2026. Thaysen said further declines are possible absent regulatory change, but the company’s core business remains resilient.

Catalysts in Upcoming Quarters

Over the coming quarters, our analysts will be monitoring (1) adoption rates and revenue contributions from recently launched products like the NovaSeq X and MiSeq i100 platforms, (2) the effectiveness of tariff mitigation strategies and related cost controls, and (3) whether clinical demand can continue to offset persistent research and China headwinds. Developments in regulatory negotiations with Chinese authorities and the rollout of new multi-omics solutions will also be important factors to watch.

Illumina currently trades at $101, up from $79.54 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

Market indices reached historic highs following Donald Trump’s presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth.

While this has caused many investors to adopt a "fearful" wait-and-see approach, we’re leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.